Sales of the company’s spinal implants and heart defibrillators, which account for about 40 percent of total sales, had been weak for more than a year and were down 5 percent this quarter as well. Overall revenue reached $4.13 billion and was boosted by sales of heart valves, stents and other upgraded products.
Related Articles on Medical Devices:
FDA Clears Aptus Endosystems EndoStapling System
Doctors Question the Value of Robot-Assisted Surgery
FDA Studying New Heart Stents that Stretch After Implantation
